Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 801–900 of 4,628
Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial
Richeldi, L., Schiffman, C., Behr, J., Inoue, Y., Corte, T. J., Cottin, V., Jenkins, G. R., Nathan, S. D., Raghu, G., Walsh, S. L. F., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202401-0116oc · Cited by 60
Self-citationIdiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
Richeldi, L., Rubin, A. S., Avdeev, S. N., Udwadia, Z. F., & Xu, Z. (2015) · BMC Medicine · doi:10.1186/s12916-015-0495-0 · Cited by 54
Self-citationEvaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres
Jo, H. E., Corte, T. J., Moodley, Y. P., Levin, K., Westall, G. P., Hopkins, P. M.-A., Chambers, D. C., & Glaspole, I. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0179-3 · Cited by 57
Increased Expression of CC16 in Patients with Idiopathic Pulmonary Fibrosis
Buendía-Roldán, I., Ruiz, V., Sierra, P., Montes, E., Ramírez, R., Vega, A., Salgado-Aguayo, A. R., Vargas, M. H., Mejía, M. E., Pardo, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168552 · Cited by 53
Self-citationTomos, I. P., Tzouvelekis, A., Aidinis, V., Manali, E. D., Bouros, E., Bouros, D. E., & Papiris, S. A. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1300533 · Cited by 57
The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies
Tanizawa, K., Handa, T., Nakashima, R., Kubo, T., Hosono, Y., Watanabe, K., Aihara, K., Ikezoe, K., Sokai, A., Nakatsuka, Y., et al. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.04.007 · Cited by 51
Li, H., Yu, H., Zhang, H., Ying, W., Li, D., Ge, Y., Ying, B., Cheng, B., Lian, Q., & Jin, S. (2017) · Scientific Reports · doi:10.1038/srep46754 · Cited by 58
Τzouvelekis, Α., Karampitsakos, Τ., Gomatou, G., Bouros, E., Tzilas, V., Manali, E., Tomos, I. P., Trachalaki, A., Kolilekas, L., Korbila, I. P., et al. (2019) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2019.101880 · Cited by 51
Kreuter, M., Wuyts, W. A., Wijsenbeek, M. S., Bajwah, S., Maher, T. M., Stowasser, S., Male, N., Stansen, W., Schoof, N., Orsatti, L., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-1298-1 · Cited by 60
Self-citationRecent advances in rheumatoid arthritis-associated interstitial lung disease
Juge, P., Crestani, B., & Dieudé, P. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000710 · Cited by 52
Campiani, G., Cavella, C., Osko, J. D., Brindisi, M., Relitti, N., Brogi, S., Saraswati, A. P., Federico, S., Chemi, G., Maramai, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00184 · Cited by 66
Salisbury, M. L., Xia, M., Murray, S., Bartholmai, B. J., Kazerooni, E. A., Meldrum, C. A., Martinez, F. J., & Flaherty, K. R. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.07.016 · Cited by 51
Self-citationIdiopathic Interstitial Pneumonia Associated With Autoantibodies
Collins, B. F., Spiekerman, C. F., Shaw, M. A., Ho, L. A., Hayes, J. M., Spada, C. A., Stamato, C. M., & Raghu, G. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.03.004 · Cited by 54
Self-citationMatsuda, T., Taniguchi, H., Ando, M., Kondoh, Y., Kimura, T., Kataoka, K., Nishimura, K., Nishiyama, O., Sakamoto, K., & Hasegawa, Y. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7019 · Cited by 60
Self-citationYoon, H., Kim, T. H., Seo, J. B., Lee, S. M., Lim, S., Lee, H. N., Kim, N., Han, M., Kim, D. S., & Song, J. W. (2018) · Respirology · doi:10.1111/resp.13387 · Cited by 54
Self-citationInterstitial lung disease and obstructive sleep apnea
Khor, Y. H., Ryerson, C. J., Landry, S. A., Howard, M. E., Churchward, T. J., Edwards, B. A., Hamilton, G. S., & Joosten, S. A. (2021) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2021.101442 · Cited by 55
Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease
Selva-O’Callaghan, A., Romero-Bueno, F., Araguás, E. T., Gil‐Vila, A., Ruiz‐Rodríguez, J. C., Sánchez‐Pernaute, O., & Pinal‐Fernandez, I. (2021) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-021-00186-x · Cited by 50
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
Brown, K. K., Inoue, Y., Flaherty, K. R., Martínez, F. J., Cottin, V., Bonella, F., Cerri, S., Danoff, S. K., Jouneau, S., Goeldner, R.-G., et al. (2022) · Respirology · doi:10.1111/resp.14231 · Cited by 59
Self-citationPost-COVID-19 Pulmonary Fibrosis
Mohammadi, A., Balan, I., Yadav, S., Matos, W. F., Kharawala, A., Gaddam, M., Sarabia, N., Koneru, S. C., Suddapalli, S. K., & Marzban, S. (2022) · Cureus · doi:10.7759/cureus.22770 · Cited by 80
“SENCIS trial, a study to investigate the effects of Nintedanib on categorical changes in forced vital capacity (FVC) and other measures of ILD progression, has shown that subjects with systemic sclerosis-associated ILD (SSc‐ILD) have a clinically relevant benefit on the progression [55].”
BackgroundLncRNA DACH1 protects against pulmonary fibrosis by binding to SRSF1 to suppress CTNNB1 accumulation
Sun, J., Jin, T., Niu, Z., Guo, J., Guo, Y., Yang, R., Wang, Q., Gao, H., Zhang, Y., Li, T., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.04.006 · Cited by 58
Jouneau, S., Rousseau, C., Léderlin, M., Lescoat, A., Kerjouan, M., Chauvin, P., Paz, D. L., Guillot, S., Oger, E., Vernhet, L., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.05.001 · Cited by 54
Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis
Ma, H., Liu, S., Li, S., & Xia, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.918771 · Cited by 63
Delivery of anti-microRNA-21 by lung-targeted liposomes for pulmonary fibrosis treatment
Yan, L., Su, Y., Hsia, I., Xu, Y. D., Vincent–Chong, V. K., Mojica, W. D., Seshadri, M., Zhao, R., & Wu, Y. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.02.031 · Cited by 55
Plichta, J., Kuna, P., & Panek, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1207641 · Cited by 64
“On the other hand, ZEPHYRUS-2 aims to assess the efficacy and safety of pamrevlumab in patients who have undergone other IPF therapies, such as pirfenidone (101) or nintedanib (102).”
BackgroundSarcoidosis-associated pulmonary fibrosis: joining the dots
Bandyopadhyay, D., & Mirsaeidi, M. S. (2023) · European Respiratory Review · doi:10.1183/16000617.0085-2023 · Cited by 56
The Role of Immune Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis
Xu, Y., Lan, P., & Wang, T. (2023) · Medicina · doi:10.3390/medicina59111984 · Cited by 68
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials
Collard, H. R., Bradford, W. Z., Cottin, V., Flaherty, K. R., King, T. E., Koch, G. G., Kolb, M. R. J., Martínez, F. J., Montgomery, B., Raghu, G., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00200614 · Cited by 55
Self-citationCognitive function in idiopathic pulmonary fibrosis
Bors, M., Tomic, R., Perlman, D., Kim, H. J., & Whelan, T. P. M. (2015) · Chronic Respiratory Disease · doi:10.1177/1479972315603552 · Cited by 53
Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer
Dallinger, C., Trommeshauser, D., Marzin, K., Liesener, A., Kaiser, R., & Stopfer, P. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.752 · Cited by 52
Connective tissue disease-related interstitial lung disease
Demoruelle, M. K., Mittoo, S., & Solomon, J. J. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.04.006 · Cited by 55
Antifibrotics in chronic liver disease: tractable targets and translational challenges
Ramachandran, P., & Henderson, N. C. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30110-8 · Cited by 50
Tsutsumi, T., Nagaoka, T., Yoshida, T., Wang, L., Kuriyama, S., Suzuki, Y., Nagata, Y., Harada, N., Kodama, Y., Takahashi, F., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214697 · Cited by 55
Zou, R. H., Kass, D. J., Gibson, K. F., & Lindell, K. O. (2020) · Pulmonary Therapy · doi:10.1007/s41030-019-00108-2 · Cited by 54
Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
Salisbury, M. L., Conoscenti, C., Culver, D. A., Yow, E. S., Neely, M. L., Bender, S. D., Hartmann, N., Palmer, S. M., & Leonard, T. B. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201912-880oc · Cited by 56
Swigris, J. J., Andrae, D. A., Churney, T., Johnson, N., Scholand, M. B., White, E. S., Matsui, A., Raimundo, K., & Evans, C. J. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0415oc · Cited by 54
Derlin, T., Jäger, B., Jonigk, D. D., Apel, R. M., Freise, J., Shin, H., Weiberg, D., Warnecke, G., Roß, T. L., Wester, H., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.08.2043 · Cited by 57
Treatable traits: a comprehensive precision medicine approach in interstitial lung disease
Khor, Y. H., Cottin, V., Holland, A. E., Inoue, Y., McDonald, V. M., Oldham, J. M., Renzoni, E. A., Russell, A., Strek, M. E., & Ryerson, C. J. (2023) · European Respiratory Journal · doi:10.1183/13993003.00404-2023 · Cited by 57
Self-citationAbdalla, M., Sabbineni, H., Prakash, R., Ergul, A., Fagan, S. C., & Somanath, P. R. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13203 · Cited by 53
A comparison of visual and quantitative methods to identify interstitial lung abnormalities
Kliment, C. R., Araki, T., Doyle, T. J., Gao, W. D., Dupuis, J., Latourelle, J. C., Zazueta, O. E., Fernandez, I. E., Nishino, M., Okajima, Y., et al. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0124-x · Cited by 55
Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?
Rangarajan, S., Locy, M. L., Luckhardt, T., & Thannickal, V. J. (2016) · Drugs · doi:10.1007/s40265-015-0523-6 · Cited by 56
Update on Pulmonary Fibrosis: Not All Fibrosis Is Created Equally
Smith, M. L. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0288-sa · Cited by 52
Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges
Lajoie, A., Bonnet, S., & Provencher, S. (2017) · Pulmonary Circulation · doi:10.1177/2045893217710639 · Cited by 58
Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
Rodríguez-Portal, J. A. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0221-9 · Cited by 54
Roach, K. M., Sutcliffe, A., Matthews, L., Elliott, G., Newby, C., Amrani, Y., & Bradding, P. (2018) · Scientific Reports · doi:10.1038/s41598-017-18555-9 · Cited by 50
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis
Harari, S. A., Caminati, A., Poletti, V. E., Confalonieri, M., Gasparini, S., Lacedonia, D., Luppi, F., Pesci, A., Sebastiani, A., Spagnolo, P., et al. (2018) · Respiration · doi:10.1159/000487711 · Cited by 53
Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms
Grillo, F., Florio, T., Ferraù, F., Kara, E., Fanciulli, G., Faggiano, A., Colao, A. A. L., & _, _. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0531 · Cited by 53
“It is approved by EMA and FDA for the treatment of locally advanced, metastatic or locally recurrent non-smallcell lung cancer and idiopathic pulmonary fibrosis (FDA only) (Richeldi et al. 2014).”
BackgroundThe Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ
Zmajkovicova, K., Menyhart, K., Bauer, Y., Studer, R. O., Renault, B., Schnoebelen, M., Bolinger, M., Nayler, O., & Gatfield, J. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0142oc · Cited by 59
Translational research in pulmonary fibrosis
Mathai, S. K., & Schwartz, D. A. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.001 · Cited by 53
Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosis
Sheth, J. S., Xia, M., Murray, S., Martinez, C. H., Meldrum, C. A., Belloli, E. A., Salisbury, M. L., White, E. S., Holtze, C. H., & Flaherty, K. R. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.01.008 · Cited by 53
Self-citationFois, A. G., Sotgiu, E., Scano, V., Negri, S., Mellino, S., Zinellu, E., Pirina, P., Pintus, G., Carru, C., Mangoni, A. A., et al. (2020) · Antioxidants · doi:10.3390/antiox9111064 · Cited by 52
“In 2014, the Food and Drug Administration approved nintedanib and pirfenidone for IPF treatment because of their ability to retard disease progression [14,15].”
BackgroundJäger, B., Seeliger, B., Terwolbeck, O., Warnecke, G., Welte, T., Müller, M., Bode, C., & Prasse, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.642855 · Cited by 56
“Interestingly, both approved antifibrotic agents for the treatment of IPF (nintedanib and pirfenidone) have been shown to reduce IL-1ß expression in lung tissues (53, 54), which might be a mechanism for the reduced risk of acute exacerbation in patients receiving antifibrotic treatment (55, 56).”
BackgroundA bird’s eye view of fibroblast heterogeneity: A pan‐disease, pan‐cancer perspective
Pradhan, R., Krishnamurty, A. T., Fletcher, A. L., Turley, S. J., & Müller, S. (2021) · Immunological Reviews · doi:10.1111/imr.12990 · Cited by 53
Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments
Fleetwood, K., McCool, R., Glanville, J., Edwards, S. C., Gsteiger, S., Daigl, M., & Fisher, M. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.3-b.s5 · Cited by 49
Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer
Peng, M., Deng, J., & Li, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02167-9 · Cited by 58
The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet)
de Andrade, J. A., Schwarz, M. I., Collard, H. R., Gentry-Bumpass, T., Colby, T. V., Lynch, D. A., & Kaner, R. J. (2015) · CHEST Journal · doi:10.1378/chest.14-2889 · Cited by 54
Self-citationHolland, A. E., Dowman, L., & Hill, C. J. (2015) · Respiration · doi:10.1159/000370126 · Cited by 53
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review
Luppi, F., Cerri, S., Taddei, S., Ferrara, G., & Cottin, V. (2015) · Internal and Emergency Medicine · doi:10.1007/s11739-015-1204-x · Cited by 56
Self-citationMembrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis
Bardou, O., Menou, A., Francois, C., Duitman, J., von der Thüsen, J. H., Borie, R., Sales, K. U., Mutze, K., Castier, Y., Sage, É., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201502-0299oc · Cited by 50
Normativa sobre el tratamiento farmacológico de la fibrosis pulmonar idiopática
Xaubet, A., Molina‐Molina, M., Acosta, O., Bollo, E., Castillo, D., Fernández‐Fabrellas, E., Rodríguez-Portal, J. A., Valenzuela, C., & Ancochea, J. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2016.12.011 · Cited by 58
Smoking-associated interstitial lung disease: update and review
Dawod, Y., Cook, N. E., Graham, W. B., MADHANI-LOVELY, F. K., & Thao, C. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1766971 · Cited by 55
Ihara, H., Mitsuishi, Y., Kato, M., Takahashi, F., Tajima, K., Hayashi, T., Hidayat, M., Winardi, W., Wirawan, A., Hayakawa, D., et al. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.01.003 · Cited by 55
Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells
Huang, Y., Oldham, J. M., Ma, S., Unterman, A., Liao, S.-Y., Barros, A. J., Bonham, C. A., Kim, J. S., Vij, R., Adegunsoye, A., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202008-3093oc · Cited by 57
Merkt, W., Zhou, Y., Han, H., & Lagares, D. (2021) · Wound Repair and Regeneration · doi:10.1111/wrr.12952 · Cited by 71
“Up 147–149 Although these drugs slow down the rate of progression of fibrosis, they do not halt or reverse established fibrosis.”
Liu, Q., Bi, Y., Song, S., Zhu, K., Qiao, X., Wang, H., & Ji, G. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03449-7 · Cited by 53
The current landscape of antifibrotic therapy across different organs: A systematic approach
Fuster‐Martínez, I., & Calatayud, S. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107245 · Cited by 64
Black, K. E., Berdyshev, E. V., Bain, G., Castelino, F. V., Shea, B. S., Probst, C. K., Fontaine, B. A., Bronova, I. A., Goulet, L., Lagares, D., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201500197r · Cited by 53
Preventive effects of vitamin D treatment on bleomycin-induced pulmonary fibrosis
Zhang, Z., Yu, X., Xia, F., Liang, A., Zhang, Y., Gu, P., Zeng, Y., He, J., Zhu, H., Li, S., et al. (2015) · Scientific Reports · doi:10.1038/srep17638 · Cited by 49
miR-323a-3p regulates lung fibrosis by targeting multiple profibrotic pathways
Ge, L., Habiel, D. M., Hansbro, P. M., Kim, R., Gharib, S. A., Edelman, J. D., Königshoff, M., Parimon, T., Brauer, R., Huang, Y., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.90301 · Cited by 52
Self-citationPlasma membrane wounding and repair in pulmonary diseases
Cong, X., Hubmayr, R. D., Li, C., & Zhao, X. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00486.2016 · Cited by 49
Chronic Lung Allograft Dysfunction: Evolving Concepts and Therapies
Derhovanessian, A., Wallace, W. D., Lynch, J. P., Belperio, J. A., & WEIGT, S. S. (2018) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1618567 · Cited by 50
Jee, A. S., & Corte, T. J. (2019) · Drugs · doi:10.1007/s40265-019-01178-x · Cited by 51
Amariei, D. E., Dodia, N., Deepak, J., Hines, S. E., Galvin, J. R., Atamas, S. P., & Todd, N. W. (2019) · Medicina · doi:10.3390/medicina55090580 · Cited by 58
“This loss of normally functioning alveolar capillary units results in a loss of effective surface area for gas exchange, ventilation-perfusion inequality, and a reduced DLCO [12,32,33].”
BackgroundAsahina, H., Oizumi, S., Takamura, K., Harada, T., Harada, M., Yokouchi, H., Kanazawa, K., Fujita, Y., Kojima, T., Sugaya, F., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.020 · Cited by 50
Sun, S., Han, R., Hou, S.-S., Yi, H.-Q., Chi, S.-J., & Zhang, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110119 · Cited by 50
Cheng, K., Liu, C., & Rao, G. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200514082425 · Cited by 55
Interstitial lung diseases in children
Nathan, N., Berdah, L., Delestrain, C., Siléo, C., & Clément, A. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2019.06.007 · Cited by 60
Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
Lancaster, L., Goldin, J., Trampisch, M., Kim, G. H., Ilowite, J., Homik, L., Hotchkin, D. L., Kaye, M., Ryerson, C. J., Mogulkoc, N., et al. (2020) · The Open Respiratory Medicine Journal · doi:10.2174/1874306402014010022 · Cited by 48
Biondini, D., Cocconcelli, E., Bernardinello, N., Lorenzoni, G., Rigobello, C., Lococo, S., Castelli, G., Baraldo, S., Cosio, M. G., Gregori, D., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01694-z · Cited by 48
Kalluri, M., Luppi, F., Vancheri, A., Vancheri, C., Balestro, E., Varone, F., Moğulkoç, N., Cacopardo, G., Bargagli, E., Renzoni, E. A., et al. (2021) · European Respiratory Review · doi:10.1183/16000617.0026-2021 · Cited by 55
Self-citationMolecular Signatures of Idiopathic Pulmonary Fibrosis
Konigsberg, I. R., Borie, R., Walts, A. D., Cardwell, J., Rojas, M., Metzger, F., Hauck, S. M., Fingerlin, T. E., Yang, I. V., & Schwartz, D. A. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0546oc · Cited by 59
Colombi, D., Dinkel, J., Weinheimer, O., Obermayer, B., Buzan, T., Nabers, D., Bauer, C. C., Oltmanns, U., Palmowski, K., Herth, F. J. F., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130653 · Cited by 53
The prognostic significance of pneumothorax in patients with idiopathic pulmonary fibrosis
Nishimoto, K., Fujisawa, T., Yoshimura, K., Enomoto, Y., Enomoto, N., Nakamura, Y., Inui, N., Sumikawa, H., Johkoh, T., Colby, T. V., et al. (2018) · Respirology · doi:10.1111/resp.13219 · Cited by 47
Holtze, C. H., Freiheit, E., Limb, S. L., Stauffer, J. L., Raimundo, K., Pan, W. T., Flaherty, K. R., & Kim, H. J. (2020) · Respiratory Research · doi:10.1186/s12931-020-1315-4 · Cited by 52
Self-citationPDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis
Paolini, C., Agarbati, S., Benfaremo, D., Mozzicafreddo, M., Svegliati, S., & Moroncini, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073904 · Cited by 55
Yu, W.-K., Chen, W., Su, V. Y., Shen, H., Wu, H.-H., Chen, H., & Yang, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158193 · Cited by 54
Allanore, Y., Vonk, M. C., Distler, O., Azuma, A., Mayes, M. D., Gahlemann, M., James, A., KOHLBRENNER, V. M., Alves, M., Khanna, D., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222564 · Cited by 53
Self-citationSpagnolo, P., Tonelli, R., Samarelli, A. V., Castelli, G., Cocconcelli, E., Petrarulo, S., Cerri, S., Bernardinello, N., Clini, E. M., Saetta, M. P., et al. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2114897 · Cited by 45
Therapeutic strategies to target connective tissue growth factor in fibrotic lung diseases
Isshiki, T., Naiel, S., Vierhout, M., Otsubo, K., Ali, P., Tsubouchi, K., Yazdanshenas, P., Kumaran, V. R., Dvorkin‐Gheva, A., Kolb, M. R. J., et al. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108578 · Cited by 53
Self-citationDong, S., Fang, H., Zhu, J., Wu, Z., Liu, Y., Zhu, J., Ma, B., Chen, Q., & Yang, Y. (2025) · ACS Nano · doi:10.1021/acsnano.4c15130 · Cited by 55
Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF
Milger, K., Kneidinger, N., Neurohr, C., Reichenberger, F., & Behr, J. (2015) · European Respiratory Journal · doi:10.1183/13993003.00584-2015 · Cited by 50
Awad, K. S., Elinoff, J. M., Wang, S., Gairhe, S., Ferreyra, G. A., Cai, R., Sun, J., Solomon, M. A., & Danner, R. L. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00303.2015 · Cited by 53
Cardiac manifestations of idiopathic pulmonary fibrosis
Agrawal, A., Verma, I., Shah, V., Agarwal, A., & Sikachi, R. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01023 · Cited by 50
Taniguchi, H., Xu, Z., Azuma, A., Inoue, Y., Li, H., Fujimoto, T., Bailes, Z., Schlenker‐Herceg, R., & Dong Soo, K. I. M. (2016) · Respirology · doi:10.1111/resp.12852 · Cited by 49
Self-citationNew Therapies for the Treatment of Renal Fibrosis
Liu, F., & Zhuang, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8871-2_31 · Cited by 51
Martínez, F. J., Afzal, A. S., Smith, J. A., Ford, A. P. D. W., Li, J. J., Li, Y., Kitt, M. M., the Chronic Cough in IPF Study Group, Hussain, I., Sher, M., et al. (2021) · Pulmonary Therapy · doi:10.1007/s41030-021-00162-9 · Cited by 51
Self-citationPulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD
Nolan, C. M., Polgar, O., Schofield, S. J., Patel, S., Barker, R. E., Walsh, J. A., Ingram, K. A., George, P. M., Molyneaux, P. L., Maher, T. M., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.10.021 · Cited by 63
Di Martino, E., Provenzani, A., Vitulo, P., & Polidori, P. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028020964451 · Cited by 46
King, C. S., Flaherty, K. R., Glassberg, M. K., Lancaster, L., Raghu, G., Swigris, J. J., Argula, R. G., Dudenhofer, R. A., Ettinger, N. A., Feldman, J., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202107-864oc · Cited by 52
Self-citationLee, J. S., White, E., Freiheit, E., Scholand, M. B., Strek, M. E., Podolanczuk, A. J., Patel, N. M., Bascom, R., Belloli, E. A., Bhatt, N., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.03.025 · Cited by 47
Self-citationAspirin alleviates pulmonary fibrosis through PI3K/AKT/mTOR-mediated autophagy pathway
Peng, J., Xiao, X., Li, S., Lyu, X., Gong, H., Tan, S., Dong, L., Sanders, Y. Y., & Zhang, X. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112085 · Cited by 49
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.